Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Shares Slide Nearly 15 Percent on News of Goodwill Asset Impairment

NEW YORK, Sept. 23 (GenomeWeb News) - Shares of Gene Logic's are down 14.8 percent, or $.83, at $4.82 in afternoon trading following news yesterday that the value of the goodwill asset from its 2003 acquisition of TherImmune Research is impaired.

 

The company will announce the amount of the impairment by Nov. 9 after completing its review with a third-party valuation specialist.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.